EU · Phase II/III · Amyotrophic lateral sclerosis
EU ALS Phase II and III trials: sites, investigators, CROs and recruitment competition
European ALS trial activity repeatedly returns to a small specialist network. Five centres each contribute to three reviewed Phase II or III programs, Philippe Corcia contributes to five, and the largest current recruiting networks are PREVAiLS and UNITE-ALS.
Top 5 sites · 17 Phase II/III ALS trials
Five specialist centres each contribute to three reviewed ALS programs
Three of the five are in Germany, alongside University Medical Center Utrecht and Beaumont Hospital. Their recurrence highlights the concentration of European ALS trial experience.
Trial participation indicates documented ALS study experience, not current capacity or recruitment performance.
Top 5 investigators · 17 Phase II/III ALS trials
Philippe Corcia contributes to five reviewed ALS programs
Susanne Petri follows with four. Leonard van den Berg, Caroline Ingre and Jessica Mandrioli each contribute to two reviewed programs.
Counts describe documented participation in the reviewed programs. Historical trial activity does not establish present availability or patient access.
CRO experience · Documented Phase II/III ALS involvement
IQVIA has the broadest documented recurrence across reviewed programs
IQVIA is documented across three studies, followed by PPD with two and Parexel with one.
CRO recurrence indicates relevant ALS delivery experience where publicly documented. It is not a measure of CRO performance or sole-vendor responsibility.
Recruitment competition · Current European studies
PREVAiLS and UNITE-ALS create the largest active recruitment footprints
The two multinational programs account for 59 listed EU sites. Three smaller Phase II studies recruit within single-country networks.
| Study | Phase | EU countries | EU sites | EU planned participants |
|---|---|---|---|---|
| PREVAiLS | III | 9 | 30 | 420 |
| UNITE-ALS | II | 9 | 29 | 206 |
| TCIM-ELAII | II | 1 | 2 | 100 |
| RituxALS01 | II | 1 | 3 | 52 |
| STEMALS | II | 1 | 4 | 30 |
Recruiting status reflects current European trial records and sponsor status on 21 September 2026. VHB937 is excluded after Novartis discontinued its ALS development program on 16 September 2026.
Source: EU Clinical Trials Information System trial records and publicly documented ALS trial networks, reviewed 21 September 2026.